Background: Acute cardiotoxicity due to anthracyclines is a rare, but life-threatening event. Interindividual sensitivity to anthracyclines is highly variable and cannot be predicted for the individual patient.
Introduction
Anthracyclines, most commonly daunorubicin, idarubicin or mitoxantrone are highly efficacious antineoplastic agents for acute myeloid leukemia (AML). However, their therapeutic potential is limited by the ocurrence of cardiotoxicity [1] [2] [3] [4] [5] [6] .
Three distinct types of anthracycline-induced cardiotoxicity have been described [7] . Chronic cardiotoxicity resulting in cardiomyopathy is well known and clinically the most important form [2, 10] . Chronic cardiomyopathy usually occures within one year of treatment [2] . The cumulative dose is a well known important risk factor. Today, late onset of anthracycline-induced cardiotoxicity causing ventricular dysfunction [11] [12] [13] and arrhythmia [14] [15] [16] is recognised more often than earlier. Its manifestations occure years or decades after a prolonged asymptomatic period.
The acute injury becomes clinically manifest during or immediately after anthracycline administration long before the assumed total cumulative toxic dose is reached. However, with the current cytotoxic drug regimens it is thought to be a relatively rare unwanted side effect. Clinicians are often not aware of the potential risk and less severe episodes are most likely missed. Acute cardiotoxicity presents mainly with transient arrhythmias or ST/T changes in ECG [8] , with a pericarditis-myocarditis syndrome or acute cardiac decompensation [9] .
Aim of this retrospective study is to analyse the frequency and clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukemia.
Patients and methods
The medical records of 165 patients treated for acute leukemia between 1990 and 1996 at the University Hospital of Zurich. Switzerland, were reviewed. All patients with known pre-existing heart disease, including coronary artery disease or risk factors for it, heart disease due to the malignancy or mediastinal radiation were excluded.
Included were patients who during or immediately after administration of combination chemotherapy with anthracycline developed clinical or radiological evidence oft left ventricular (LV) decompensation with dyspnea and pulmonary rales, cardiomegaly or signs of pulmonary hypertension on chest X-ray.
Pathologic-anatomical manifestations for anthracycline associated cardiotoxicity were hypertrophy [17, 18] , cardiomegaly [17. 19] , pericarditis [2, 7. 17, 20] , pericardial effusion [17] and myocarditis [7] . The histological criteria were myofibrillar loss, distension of the sarcoplasmatic reticulum. and cytoplasmatic vacuolisation, diffuse cell damage (total loss of contractile elements, loss of organellcs, milochondrial and nuclear degeneration) [I],
Results
In our series, six males and one female, age 19 to 66 years (median 41) met the criteria of anthracyclineassociated acute cardiotoxicity. All patients were treated with curative intention, six for a de novo AML (FAB classification: two patients MO, two patients Ml, one patient M4, one patient M6) and one for relapsing disease.
All patients but one received conventional doses of anthracycline for treatment.
In one patient a ten-fold overdose of mitoxantrone was accidentally infused.
Clinical course and findings
Clinical symptoms were those of left (6 of 7) or biventricular heart failure (1 of 7) with dyspnea and orthopnea, tachycardia, pulmonary oedema and elevated jugular venous pressure. The first symptoms occured in three patients during the first course, in three patients during the second and in one patient after the third course of treatment. All of them recoverd from the first episode but six patiens died of cardiotoxicity during the following course with anthracycline. Only one patient recovered again.
At the time of clinical symptoms of cardiac toxicity the chest X-ray was abnormal in all seven patients. Six of seven had a cardiomegaly, two of seven signs of pulmonary venous congestion and two of seven pleural effusion. In three patients pulmonary venous congestion as well as pleural effusion were present.
An electrocardiogram was registred in six of seven patients before starting chemotherapy. In two of them (P4 and P5) an incomplete right bundle branch block was pre-existent. On treatment, a rapid atrial flutter became manifest in one patient (PI), premature ventricular complexes in another (P3). One patient (P7) developed supraventricular arrhythmia and polymorph premature ventricular complexes. In four patients (PI, P4, P6 and P7) diffuse repolarisation abnormalities appeared. In one patient an AV-block 1° occurred in combination with a total right bundle branch block.
An echocardiography was done in three patients (PI, P4, and P6) after the occurrence of cardiac abnormalities: two patients (PI, P4) had a haemodynamically not relevant pericardial effusions with normal ejection fraction, one patient (P6) a decreased ejection fraction of 30%.
Treatment and outcome
Six patients (PI, P3-7) needed specific heart failure treatment with diuretics, angiotensin converting enzyme inhibitors (P4, P6) and catecholamines (P3, P5, P6). Three patients received digitalis (PI, P6, P7), and one patient (P7) lidocaine.
All seven patients died 65-450 (median 129) days after start of chemotherapy. The death of six patients was due to acute cardiotoxicity. Anthracycline-associated cardiopathy was confirmed by histo-pathological findings. One patient recovered from a clinically well documented episode of severe heart failure but died later from progressing disease. An autopsy was refused.
Autopsy
Autopsy was performed in six of seven patients (P1-P5, P7). Macroscopically, the heart was hypertrophic in all six patients, dilatated in three (P4, P5, P7). In four (PI, P2, P4, P5) pericardial effusion was present. A fibrous, sterile peri-/epicarditis was seen in one (PI), epicardial bleeding in two (P3, P4), endocardial haemorrhage in one (P3) patient. Microscopically typical morphological features of acute anthracycline-induced cardiotoxicity such as myocardial fibrosis and perinuclear vacuolisated myocytes were seen in five patients (PI, P2, P4, P5, P7). One (P3) had endomyocardial fibrosis. In three patients (P3, P4, P7) myocardial necrosis was seen: in one (P3) myocardial necrosis was subendocardial, in one (P7) diffuse and one patient (P2) had papillary muscle necrosis. All six patients had normal, wide coronary arteries. Additionally, one patient (P3) had a sterile abscess (diameter 3 mm) in the left ventricle of unknown aetiology.
Discussion
Over a period of six years, 165 patients were treated for acute leukemia at the University Hospital of Zurich, Switzerland. In seven of them, acute cardiotoxicity attributable to anthracycline-based chemotherapy was observed. This is relatively a rare complication and probably often missed. The true incidence remains unknown. Patients with probable subclinical acute cardiotoxicity are missed. In this study, patients with additional cardiac risk factors were not taken into account.
The most important risk factor for the development of chronic cardiotoxicity is the total cumulative dose. In contrast, the event of acute cardiotoxicity is not predictable and occurs unexpectedly. There seems to be a large variation in individual sensitivity. Often, clinicians are not aware of the potential risk. Less severe episodes are therefore missed. In our experience, the possibility of drug-induced cardiotoxicity was taken into consideration late in the course. One reason was that these mostly young, previously healthy patients without pre-existing heart disease are in reduced general condition which is ascribed to the life-threatening disease, the aggressive treatment and its well-known side effects. Early diagnosis could contribute to the prevention of drug-induced heart failure with fatal outcome in the acute phase, possibly also reduce the rate of chronic or late-onset anthracycline-induced cardiotoxicity.
The main problem is the lack of reliable tests for early detection of subclinical cardiac tissue damage. Clinical manifestations of heart failure, ECG changes or echocardiography are neither sensitive enough nor specific in an early stage. Radioimmunoscintigraphy is sensitive, but its specificity low. Endomyocardial biopsy examination is considered to be the most sensitive and specific method for anthracycline-induced cardiotoxicity and for prediction of cardiac dysfunction [12] . This method is invasive and restricted to medical centres. Therefore, the use for routine monitoring is limited.
There ar no reliable laboratory tests for early detection of myocardial damage. The release of cardiac troponin T (cTnT) as a biomarker of doxorubicin-induced chronic cardiac injury has been evaluated in the spontaneously hypertensive rat (SHR) model. Monitoring serum levels of cTnT can detect doxorubicin-induced myocyte damage and may prove to be useful for the non-invasive evaluation of cardiac toxicity in humans [29] . Fink et al.
[30] evaluated 35 anthracycline-containing chemotherapy courses in 22 children with cancer. Within 72 hours from anthracycline therapy no increment of one of these marker proteins was detected.
Atrial natriuretic peptide (ANP), mainly from the atrium, and brain natriuretic peptide (BNP), mainly from the ventricle, provide prognostic information independent of other variables associated with a poor prognosis in patients with chronic heart failure [31] . Natriuretic peptides might be useful in the detection of subclinical left ventricular dysfunction as indication for cardiomyoathy [34, 35] . Their predictive value for clinically relevant damage is not yet known. Prospective studies have to prove their diagnostic benefit.
Strategies for prevention of anthracycline-associated cardiotoxicity have to be developed. Chelating agents like ICRF 187 (dexrazoxane) and antioxidative WR-2721 (amifostine) have been applied in combination with anthracyclines [26, 33] . Proving their efficacy is difficult again due to the lack of established tests recording already minimal cardiac damage. Early administration of the ACE inhibitor may be an other therapeutic possibility.
Acute cardiotoxicity of anthracyclines is a rare, but life-threatening event. Sensitiveness to anthracyclines is interindividually highly variable and not predictable. The awareness of potential adverse effects on cardiac performance by anthracyclines may contribute to early diagnosis and prevention of drug-induced heart failure. Reliable tests are needed for early diagnosis of subclinical myocardial damage in order to identify patients at risk.
